Cardiology Today’s Intervention’s top news in October

Cardiology Today’s Intervention compiled a list of the most-read articles posted in October on Healio.com/Intervention. This month, readers were interested in the cessation of a trial examining anticoagulation strategies after transcatheter aortic valve replacement, an innovation award given to a novel device therapy for pulmonary hypertension, trials of renal denervation and pulmonary artery denervation technologies and more.

Trial of rivaroxaban after TAVR stopped due to excess of events

Bayer sent a “Dear Healthcare Professional” letter informing clinicians that the GALILEO trial of rivaroxaban for patients who underwent TAVR was stopped due to poor outcomes in the rivaroxaban arm.

Device therapy for pulmonary hypertension wins innovation award

SAN DIEGO — A novel device to treat pulmonary hypertension won the Shark Tank Innovation Competition held at TCT 2018.

The device, developed by Aria CV Inc. of St. Paul, Minnesota, was designed for patients with various forms of pulmonary hypertension, said John Scandurra, DVM, co-founder and CEO of the company.

Renal denervation trial stopped, but technology may show promise

SAN DIEGO — A trial of a renal denervation technology in patients with resistant hypertension was stopped for futility because it was not going to be able to meet its primary endpoint, but it showed promise for improving 6-month outcomes, according to a presentation at TCT 2018.

PADN-5: Pulmonary artery denervation shows promise

SAN DIEGO — Pulmonary artery denervation showed improved outcomes in patients with combined pre- and postcapillary pulmonary hypertension, according to the randomized, sham-controlled PADN-5 trial.

More data starting to emerge about pretreatment, switching DAPT after PCI

SAN DIEGO — More information is needed regarding how to pretreat patients with dual antiplatelet therapy before PCI, but recent research has provided more evidence as to how to switch from one therapy to another after patients undergo PCI, according to two presentations at TCT 2018.

GLOBAL LEADERS: Experimental antiplatelet therapy may benefit in ACS, but not in stable CAD

SAN DIEGO — Among patients who had PCI with a drug-eluting stent, 1 month of combination ticagrelor and aspirin therapy followed by ticagrelor alone conferred better bleeding outcomes at 2 years than 1-year clopidogrel plus aspirin followed by 1-year aspirin monotherapy in patients with ACS, according to new data from the GLOBAL LEADERS study presented at TCT 2018.

NEOPRO: 2 next-generation valves confer similar outcomes in TAVR

SAN DIEGO — Patients who underwent transfemoral TAVR with one of two next-generation transcatheter heart valves had high device success, improved 30-day clinical outcomes and acceptable rates of paravalvular aortic regurgitation, according to data from the NEOPRO registry presented at TCT 2018.

Reimbursement issues raise concerns about future of peripheral interventions

SAN DIEGO — Despite the evidence for the safety, efficacy and cost-effectiveness of drug-coated balloons for peripheral interventions, their use in clinical practice has become overshadowed by fiscal concerns, according to a presentation at TCT 2018.

FAST-FFR: Angiography-derived FFR accurately classifies coronary lesions

SAN DIEGO — Fractional flow reserve derived from coronary angiography is comparable to conventional pressure wire-derived FFR for physiologic assessment of coronary stenoses, according to new findings from the FAST-FFR trial.

Recall of endovascular AAA system designated as class 1

The FDA has designated Endologix’ product recall of an endovascular abdominal aortic aneurysm system as a class 1 recall, the most serious kind. The recall affects 61,300 devices manufactured and distributed since March 2011.